Geïntegreerde diagnostiek met beeldvorming en biomarkers versnelt vroege opsporing van mondholtekanker
Deze narratieve review vat de huidige stand van zaken samen voor de diagnostiek en vroege monitoring van squameus-celcarcinoom van de mondholte. Conventionele inspectie en histopathologie blijven de diagnostische basis, terwijl adjunctieve technieken zoals narrow-band imaging, optische coherentiemicroscopie en vloeibare biopsie potentie tonen voor betere lesietriage en surveillance.
Klinische invoering van moleculaire biomarkers en kunstmatige intelligentie wordt echter nog beperkt door methodologische heterogeniteit, pre-analytische variabiliteit en onvoldoende externe validatie. Voor de oncologische praktijk onderstreept dit de noodzaak van geïntegreerde diagnostische paden die prospectief in multicenterstudies moeten worden gevalideerd om de diagnose in een eerder stadium te stellen.
Abstract (original)
Background/Objectives: Oral cavity squamous cell carcinoma (OSCC) remains a major global health burden, with outcomes strongly dependent on stage at diagnosis. Although the oral cavity is directly accessible to clinical examination, many cases are still detected at advanced stages. This narrative review aimed to summarize current trends in OSCC diagnosis and early monitoring, with emphasis on non-invasive and minimally invasive techniques and biomarkers. Methods: A semi-systematic narrative literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science using predefined combinations of OSCC-, early-detection-, imaging-, cytology-, liquid-biopsy-, salivaomics-, artificial-intelligence-, and biosensor-related terms. English-language systematic reviews, meta-analyses, reviews of reviews, translational studies, and clinically relevant original articles were prioritized, with explicit attention to oral cavity-specific evidence and clearly identified extrapolation from broader head-and-neck or oropharyngeal cancer settings. Results: Conventional oral examination and histopathological assessment of biopsy specimens remain the diagnostic foundation. Adjunctive methods may support lesion triage, biopsy-site selection, risk stratification, and early monitoring, but cannot replace tissue diagnosis. Narrow-band imaging, optical coherence tomography, and molecular brush cytology appear particularly promising for specialist assessment and surveillance. Liquid biopsy and saliva-based biomarker platforms offer translational potential, particularly for repeatable monitoring, but clinical implementation is limited by methodological heterogeneity, pre-analytical variability, inconsistent thresholds, and insufficient external validation. Artificial intelligence and biosensor platforms remain promising but largely developmental. Conclusions: Progress in early OSCC diagnosis and monitoring will most likely depend on integrated diagnostic models combining clinical examination, adjunctive imaging, minimally invasive sampling, molecular biomarkers, and computational decision-support tools, validated in prospective multicenter studies.
Dit artikel is een samenvatting van een publicatie in Cancers. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.
Lees het volledige artikelDOI: 10.3390/cancers18132088